SciELO - Scientific Electronic Library Online

 
vol.9 issue4Sodium Caprylate Stabilization of AlbuminHisthopatologic study in non-vaccinated and vaccinated mice using Salmonella typhi polysaccharidic and whole cell variants by different inoculation routes author indexsubject indexarticles search
Home Pagealphabetic serial listing  

My SciELO

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Vaccimonitor

Print version ISSN 1025-028XOn-line version ISSN 1025-0298

Vaccimonitor vol.9 no.4 Ciudad de la Habana Oct.-Dec. 2000

 

ARTICULOS ORIGINALES

 

 

Validación de un ELISA para la cuantificación de antitoxina tetánica en suero humano.

 

Validation of an ELISA for the quantitative determination of tetanus antitoxin in human serum.

 

 

Rolando Ochoa, Juan Carlos Martínez, Esther M. Fajardo, Eduardo Alvarez, Eric Estrada, Ana Margarita García, Xenia Ferriol, Rosa Blanco, Franklin Sotolongo.

Instituto Finlay. Centro de Investigación-Producción de Vacunas y Sueros. Ciudad de La Habana, Cuba.
E-mail:ochoa@finlay.edu.cu


RESUMEN

Se desarrolló un ensayo inmunoenzimático en fase sólida (ELISA) de tipo indirecto para la cuantificación de
antitoxina tetánica en suero humano, con el empleo de un estándar previamente calibrado. Las imprecisiones
intra e interensayo fueron de alrededor del 10%. Este ensayo mostró una excelente exactitud, con valores de
recuperación entre 90% y 110%. Las desviaciones del paralelismo estuvieron por debajo del 10%; éstas se
evaluaron mediante diluciones que involucraban el rango de trabajo de la curva estándar. El límite de detección
fue 0,0016 Unidades Internacionales por mL (UI/mL). El ensayo mostró una buena correlación con la prueba de
neutralización (R2=0,9862). La ecuación de ajuste lineal fue: ELISA = 0,993 ensayo de neutralización – 0,2143.
Se cuantificó la antitoxina tetánica en muestras de suero de 408 niños entre 1 a 5 años de edad,aleatoriamente seleccionados en Ciudad de La Habana y cada edad se analizó por separado. La mayor respuesta se alcanzó a los 2 años de edad, al completarse el esquema básico de inmunización. Todos los niños presentaron valores superiores al nivel mínimo protector (0,01 UI/mL).

Palabras claves: Antitoxina tetánica, ensayo inmunoenzimático, ELISA, validación.


ABSTRACT


An indirect solid-phase enzyme-linked immunosorbent assay (ELISA) was developed for the quantitation of tetanus antitoxin in human serum on the basis of a previously calibrated standard. Intra and inter-assay imprecision ranged around 10%. This assay showed an excellent accuracy with recovery values between 90% and 110%. Parallelism deviations were below 10%. They were evaluated by dilutions that covered the working range of the standard curve. The detection limit was 0.0016 International Units per mL (IU/mL). A good correlation was found between the ELISA and the neutralization test (R2= 0,9862). The fitting linear equation was: ELISA = 0,993; neutralization test – 0,2143. Tetanus antitoxin was quantified in serum samples from 408 children, 1-5 year-olds, randomly selected in Havana City. Each age was separately analyzed. The maximum response was reached at 2 years, after finishing the basic scheme of immunization. All children showed antitoxin values higher than the minimum protective level (0,01 IU/mL).

Key words: tetanus antitoxin, enzyme immunoassay, ELISA, validation.


texto completo en pdf

REFERENCIAS

1.Galazka AM. Tetanus. En: The Immunological Basis for Immunization Series. Geneva: World Health Organization; 1996.

2.Hoppenbrouwers K, Roelants M, Ethevenaux C, Vandermeulen C, Knops J, Desmyter J. The effect of reconstitution of an Haemophilus influenzae type b tetanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow up. Vaccine 1999;17:2588-98.

3. Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis 1999; 28:995-1001.

4. Pichichero ME, Latiolais T, Bernstein DI, Hosbach P, Christian E, Vidor E, et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid acellular pertussis / purified capsular polysaccharide of Haemophilus influenzae type b tetanus toxoid vaccine in two, four and six month old infants. Pediatr Infect Dis J 1997;16:863-70.

5.Zaffran M. Immunize every child: GAVI strategy for sustainable immunization services. En: GAVI Global Alliance for Vaccines and Immunization. Second Board Meeting; Switzerland: Davos; 2000:9-44.

6. Peel MM. Measurement of tetanus antitoxin: II, toxin neutralization. J Biol Stand 1980;8:191-207.

7. Winsnes R, Hendriksen C, Sesardic D, Akkermans A, Daas A. Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use. Dev Biol Stand. 1999; 101:277-88.

8. World Health Organization. Biological Substances. International Standards and Reference Reagents. Geneva; 1991.

9. Plikaytis BD, Carlone GM, Turner SH, Gheesling LL, Holder PF. Program ELISA user's manual. Atlanta: Centers for Disease Control and Prevention; 1993.

10. Plikaytis BD, Turner SH, Gheesling LL, Carlone GM. Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J Clin Microbiol 1991;29:1439-1446.

11. Ochoa R, Martínez JC, Ferriol X, García AM, Estrada E, Blanco R, et al. Principios y procedimientos para la validación de inmunoensayos cuantitativos empleados para evaluar la inmunogenicidad de vacunas. VacciMonitor 1999; 8(10):9-13.

12. Chaloner-Larsson G, Anderson R, Egan A. A WHO guide to good manufacturing practice (GMP) requirements. Part 2: Validation. Validation of analytical assays. WHO Geneva, 1997:65-95.

13. STATGRAPHICS Plus for WINDOWS [computer program]. Version 1.0. Statistical Graphics Corp, USA, 1994.

14. Lwanga SK, Lemeshow S. Determinación del tamaño de las muestras en los estudios sanitarios. Manual Práctico.. Ginebra: Organización Mundial de la Salud; 1991.

15. Dokmetjian J, Della Valle C, Lavigne V, De Lujan CM, Manghi MA. A possible explanation for the discrepancy between ELISA and neutralizing antibodies to tetanus toxin.Vaccine. 2000; 18:2698-2703.

16. Ann NQ, Hong HA, Nhon TN, Think ND, Van NT, Hendriks J. Tetanus antibodies measured by the toxin binding inhibition test (ToBI) in mothers and children in the Neonatal Tetanus Program in Vietnam. Dev Biol Stand 1999;101:247-53.

17. Hong HA, Ke NT, Nhon TN, Think ND, Van der Gun JW, Hendriks JT, et al. Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam. Bull World Health Organ. 1996; 74(3):275-82.

18. Pryor T, Onarecker C, Coniglione T. Elevated antitoxin titers in a man with generalized tetanus. J Fam Pract 1997; 44(3):299-303.

19. De Melker HE, van der Hof S, Berbers GA, Nagelberke NJ, Rumke HC, Lonyn-van Spaendonck MA. A population-based study on tetanus antitoxin levels in the Netherlands. Vaccine 1999;18:100-8.

20. Takahashi M, Komiya T, Fukuda T, Nagaoka Y, Ishii R, Goshima F, et al. A comparison of young and aged populations for the diphtheria and tetanus antitoxin titers in Japan. Jpn J Med Sci Biol 1997;50(2):87-95.

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License